

Supporting Information

An investigation of the sodium nitroprusside effects on serum lipids in an animal model for schizophrenia by magnetic resonance study

João Guilherme de Moraes Pontes^a, João Victor Silva Nani^{b,c}, Banny Silva Barbosa Correia^a, Tássia Brena Barroso Carneiro Costa^a, Danijela Stanisic^a, Mirian A. F. Hayashi^{b,c*}, Ljubica Tasic^{a*}

^aLaboratório de Química Biológica (LQB), Departamento de Química Orgânica, Instituto de Química, Universidade Estadual de Campinas (UNICAMP), Campinas, SP 13083-970, Brazil, and INCTBio

^bDepartamento de Farmacologia, Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP), São Paulo, SP 04044-020, Brazil

^cInstituto Nacional de Ciência e Tecnologia Translacional em Medicina (INCT-TM, CNPq), Ribeirão Preto 14026, Brazil

*ljubica@unicamp.br

*mhayashi@unifesp.br

Summary

- PLS-DA using SHR as an animal model

- 2 groups (control · SHR + sNP) (Figure S1) S3
- Box plots (control · SHR + sNP 2.5 mg kg⁻¹) (Figure S2) S4
- Box plots (control · SHR + sNP 2.5 mg kg⁻¹) (Figure S3) S5
- 3 groups (control · SHR + sNP 2.5 mg kg⁻¹ · SHR + sNP 5.0 mg kg⁻¹) (Fig. S4) S6

- PLS-DA using Wistar as an animal model

- 2 groups (control · Wistar + sNP) (Figure S5) S7
- Box plots (control · SHR + sNP 2.5 mg kg⁻¹) (Figure S6) S8
- Box plots (control · SHR + sNP 2.5 mg kg⁻¹) (Figure S7) S9
- 3 groups (control · Wistar + sNP 2.5 mg kg⁻¹ · Wistar + sNP 5.0 mg kg⁻¹)
(Fig. S8) S10

- PLS-DA using SHR and Wistar as animal models

- 4 groups (SHR control · Wistar control · SHR + sNP 2.5 mg kg⁻¹
SHR + sNP 5.0 mg kg⁻¹) (Figure S9) S11
- 4 groups (Wistar control · SHR control · Wistar + sNP 2.5 mg kg⁻¹ ·
Wistar + sNP 5.0 mg kg⁻¹) (Figure S10) S12



- PLS-DA (Wistar + sNP · clozapine · haloperidol) (Figure S11) S13

- Peak Assignments

- SHR + sNP (δ 0.50 to 6.00) (Figure S12) S14
- Table S1 S14

sNP 2.5 mg.kg⁻¹

- A-)** ● Control group of SHR (1)
● SHR + sNP (2.5 mg.kg⁻¹) (2)



sNP 5.0 mg.kg⁻¹

- B-)** ● Control group of SHR (1)
● SHR + sNP (5.0 mg.kg⁻¹) (3)





Figure S1. PLS-DA of two groups using a spectral range between δ 0.50-6.00 with the exclusion of δ 1.50-1.68 and δ 4.63-4.81. **A)** Scores graph with Volcano plot (40 results with statistical significance – p -value < 0.05) – 4 samples of untreated SHR control group (blue color, group 1) + 5 samples of SHR + sNP 2.5 mg kg⁻¹ (yellow color, group 2). **B)** Scores graph with Volcano plot (11 results with statistical significance) – 4 samples of untreated SHR control group (blue color, group 1) + 5 samples of SHR + sNP 5.0 mg.kg⁻¹ (red color, group 3).




Figure S2. A) VIP scores graph of untreated SHR control group (blue color, group 1) · SHR + sNP 2.5 mg kg⁻¹ (yellow color, group 2) with box plots with p -values < 0.05. **B)** Some other box plots with statistical significance on the spectral range between δ 0.50-6.00. Abbreviation: UFA – unsaturated fatty acids. The NMR peak assignments were done based on Correia *et al.* 2021¹⁹ and Tynkkynen, 2012.²⁸




Figure S3. A) VIP scores graph of untreated SHR control group (blue color, group 1) · SHR + sNP 5.0 mg.kg⁻¹ (red color, group 3) with box plots with p -values < 0.05. **B)** Some other box plots with statistical significance on the spectral range between δ 0.50-6.00. Abbreviations: FFA – free fatty acids; UFA – unsaturated fatty acids. The NMR peak assignments were done based on Correia *et al.* 2021¹⁹ and Tynkynen, 2012.²⁸





Figure S4. PLS-DA of three groups using the following spectral range δ 0.50-6.00 with the exclusion of δ 1.50-1.68 and δ 4.63-4.81. **A)** Scores graph – 4 samples of untreated SHR control group (blue color, group 1) + 5 samples of SHR + sNP 2.5 mg.kg⁻¹ (yellow color, group 2) + 5 samples of SHR + sNP 5.0 mg.kg⁻¹ (red color, group 3); Scores graph (2D) - PC1 (32.2%) · PC2 (58.2%); **C)** VIP scores. **D)** PLS-DA cross-validation with the accuracy of 78.0%; $Q^2 = 0.29699$ and $R^2 = 0.45.072$ using five (5) components. Abbreviations: FFA – free fatty acids; UFA – unsaturated fatty acids.

sNP 2.5 mg.kg⁻¹

- A-)**
- Control group of Wistar (1)
 - Wistar + sNP (2.5 mg.kg⁻¹) (2)



sNP 5.0 mg.kg⁻¹

- B-)**
- Control group of Wistar (1)
 - Wistar + sNP (5.0 mg.kg⁻¹) (3)




Figure S5. PLS-DA of two groups using a spectral range between δ 0.50-6.00 with the exclusion of δ 1.50-1.68 and δ 4.63-4.81. **A)** Scores graph with Volcano plot (5 results with statistical significance – p -value < 0.05) – 4 samples of untreated Wistar control group (cyan color, group 1) + 5 samples of Wistar + sNP 2.5 mg.kg⁻¹ (green color, group 2). **B)** Scores graph with Volcano plot (74 results with statistical significance) – 4 samples of untreated Wistar control group (cyan color, group 1) + 5 samples of Wistar + sNP 5.0 mg.kg⁻¹ (black color, group 3).




Figure S6. Box plots with statistical significance on the spectral range between δ 0.50-6.00 of untreated Wistar control group (cyan color, group 1) · Wistar + sNP 2.5 mg.kg⁻¹ (green color, group 2). Abbreviation: PUFA – polyunsaturated fatty acids. NMR peak assignments were done based on Correia *et al.* 2021¹⁹ and Tynkkynen, 2012.²⁸




Figure S7. A) VIP scores graph of untreated Wistar control group (cyan color, group 1) · Wistar + sNP 5.0 mg.kg⁻¹ (black color, group 3) with box plots with p -values < 0.05. **B)** Some other box plots with statistical significance on the spectral range between δ 0.50-6.00. Abbreviations: ChoGPL - choline glycerophospholipids; FFA – free fatty acids; PUFA – polyunsaturated fatty acids. The NMR peak assignments were done based on Correia *et al.* 2021¹⁹ and Tynkkynen, 2012.²⁸




Figure S8. PLS-DA of three groups using the spectral range between δ 0.50-6.00 with the exclusion of δ 1.50-1.68 and δ 4.63-4.81. **A)** Scores graph (3D) – 4 samples of untreated Wistar control group (cyan color, group 1) + 5 samples of Wistar + sNP 2.5 mg.kg⁻¹ (green color, group 2) + 5 samples of Wistar + sNP 5.0 mg.kg⁻¹ (black color, group 3); **B)** Scores graph (2D) - PC1 (94.3%) · PC2 (1.6%); **C)** VIP scores. **D)** PLS-DA cross-validation with the accuracy of 90.5%; $Q^2 = 0.57651$ and $R^2 = 0.7884$ using 5 components. Abbreviation: FFA – free fatty acids.




Figure S10. PLS-DA of four groups. **A)** Scores graph (3D) – 4 samples of untreated SHR control group (dark blue color, group 1) + 4 samples of untreated Wistar control group (cyan color, group 2) + 5 samples of Wistar + sNP 2.5 mg.kg⁻¹ (green color, group 3) + 5 samples of Wistar + sNP 5.0 mg.kg⁻¹ (black color, group 4) using a spectral range between δ 0.50-6.00 with exclusion of δ 1.50-1.68 and δ 4.63-4.81; **B)** Scores graph (2D) - PC1 (40.8%) · PC2 (54.8%); **C)** VIP scores; **D)** PLS-DA cross-validation with the accuracy of 82.9%; $Q^2 = 0.83141$ and $R^2 = 0.88297$ using five (5) component. Abbreviation: FFA – free fatty acids.




Figure S11. PLS-DA of Wistar treated with sNP, haloperidol, or clozapine. **A)** Scores graph (3D) - 4 samples of Wistar untreated control group (cyan color, group 1) + 5 samples of Wistar + sNP 2.5 mg.kg⁻¹ (green color, group 2) + 5 samples of Wistar + sNP 5.0 mg.kg⁻¹ (black color, group 3) + 4 samples of Wistar + haloperidol (pink color, group 4) + 5 samples of Wistar + clozapine (purple color, group 5) using a spectral range between δ 1.30-2.60 with exclusion of δ 1.50-1.68; **B)** Scores graph (2D) - PC1 (62.3%) · PC2 (17.6%); **C)** VIP scores; **D)** PLS-DA cross-validation with the accuracy of 78.3%; $Q^2 = 0.8591$ and $R^2 = 0.8792$ using 4 components. **E)** Box plots of the original concentration of variables 1.35 and 1.49, which were assigned to free fatty acids (FFA) and 1.77 assigned to β -methylene protons of the carbonyl ($-\text{OC}(\text{O})-\text{CH}_2-\text{CH}_2-$). The NMR peak assignments were done based on Correia *et al.* 2021¹⁹ and Tynkkynen, 2012.²⁸

SHR + sNP




Figure S12. Metabolites assignment of $^1\text{H-NMR}$ spectra of untreated SHR control (black color), SHR + sNP 2.5 mg.kg^{-1} (green color), and SHR + sNP 5.0 mg.kg^{-1} (blue color) on the spectral range between δ 1.30 to 2.60. Spectral regions highlighted in gray represent the excluded area in chemometrics analysis – δ 1.50-1.68 and δ 4.63-4.81. The numbers from 1 to 7 indicate NMR peak assignments, which are related to protons in bold (Table S1) (Correia *et al.* 2021).¹⁹

Table S1. $^1\text{H-NMR}$ peak assignments (Correia *et al.* 2021)¹⁹

Peak	Chemical shift (ppm)	Assignment
1	0.75-1.00	-CH₃ protons of saturated, oleic, and linoleic acyls (omega-6)
2	0.93-1.02	-CH₃ protons of the linolenic chain (omega-3)
3	1.20-1.50	Methylene protons of aliphatic chains -(CH₂)_n
4	1.50-1.75	β -methylene protons of the carbonyl -OC(O)-CH₂-CH₂-
5	1.95-2.10	Methylene protons in the α position of double bonds -CH₂-CH=CH-
6	2.20-2.50	Methylene protons in the carbonyl α position -OC(O)-CH₂-
7	5.00	Anomeric carbon protons of galactose